The aim the study is to determine the effects of a fixed combination of indapamide in combination with calcium channel blockers (CCBs) in patients with high risk factors for coronary artery diseases and severe hypertension.Design and method:
65 patients with arterial hypertension (mean age 57 ± 16 y, 32% female) and type 2 diabetes mellitus and divided on two groups, regarding the level of BP from AMBP, were analyzed at baseline before starting therapy and 4 months follow up. The group with mild AH received fixed indapamide /amlodipine 1.5/5 mg daily and group with severe AH – indapamide /amlodipine 2.5/10 mg.Results:
After 4monts Blood pressure targets were reached by 78.0% of patients. Changes in BP were 19.8 ± 8.3/9.7 ± 7.2 mmHg for grade 1, 20.3 ± 10.5/15.6 ± 9.6 mmHg for grade 2, and 35.3 ± 16.2/19.8 ± 12.2 mmHg for grade 3 patients (p < 0.0001). The AMBP 24-h mean blood pressure decreased from 148.6 ± 12.7/78.1 ± 13.6 to 123.7 ± 6.4/77.8 ± 6.5 mmHg (p < 0.0001). Diastolic blood pressure at 16 weeks was significantly lower from baseline. (p = 0.001). Lipid profile and glucose status of the patients shown slight decrease but was without significant changes from baseline after 16 weeks of both fixed dose combination of treatment (p < 0.72). After 4mFU we found improvement of systolic BP more significant in the group with severe AH and treated with higher dose indapamide/amlodipine 2.5/10 (p = 0.01).Were found positive correlation between parameters and E/Em, ratio and a negative correlation with E/A ratio. Ankle edema was infrequent (0.1% of patients).Conclusions:
The single pill fixed combination indapamide/amlodipine was effectively and safely administered in population of high- and very high-risk hypertensive patients and may be efficacious as first-line treatment for patients with mild to moderate essential hypertension.